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Abstract: Clinical practice guidelines (CPG) are written 
with the aim of collating the most up to date information 
into a single document that will aid clinicians in provid-
ing the best practice for their patients. There is evidence 
to suggest that those clinicians who adhere to CPG deliver 
better outcomes for their patients. Why, therefore, are 
clinicians so poor at adhering to CPG? The main barriers 
include awareness, familiarity and agreement with the 
contents. Secondly, clinicians must feel that they have 
the skills and are therefore able to deliver on the CPG. 
Clinicians also need to be able to overcome the inertia of 
“normal practice” and understand the need for change. 
Thirdly, the goals of clinicians and patients are not always 
the same as each other (or the guidelines). Finally, there 
are a multitude of external barriers including equipment, 
space, educational materials, time, staff, and financial 
resource. In view of the considerable energy that has been 
placed on guidelines, there has been extensive research 
into their uptake. Laboratory medicine specialists are not 
immune from these barriers. Most CPG that include labo-
ratory tests do not have sufficient detail for laboratories 
to provide any added value. However, where appropriate 
recommendations are made, then it appears that labora-
tory specialist express the same difficulties in compliance 
as front-line clinicians.
Keywords: guidelines; quality assurance; quality indicator.
Introduction
New clinical knowledge is being published so fast that it is 
nearly impossible for any individual to keep track of new 
developments and to place those developments within a 
coherent framework. This has led to variations in practice 
and patient outcomes. The movement to develop evidence 
based clinical guidelines has evolved to help standardise 
and improve patient care. Clinical practice guidelines are 
created by a process that starts with a review and evalu-
ation of the available scientific literature which is con-
verted into an output of recommendations that embody 
both the evidence and expert opinion and may therefore 
be considered to represent best practice.
Modern medical practice has become more complex 
and interventional with new knowledge. Inevitably, this 
has forced a change in clinical practice. The old model of 
practice with a single specialist and his team of junior staff 
has been replaced by a team of specialist clinicians all of 
whom treat a different aspect of a patient’s care. More-
over, clinicians now work in defined time shifts rather 
than being available throughout the patient journey. The 
value of Clinical Practice Guidelines (CPG) is to maintain 
consistency and to ensure that everyone knows their role 
in order to reduce clinical errors. A recent case report 
has shown how minor infringements in multi-individual 
processes can lead to disasters [1]. Despite this, it is not 
always wrong to deviate from a CPG if there are good clini-
cal reasons. Indeed, CPG must always be interpreted in the 
light of patients’ concomitant disease(s) and underlying 
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risk factors. Deviation from CPG may be appropriate in 
the context of a patient’s unique situation. CPG cannot 
be written for every clinical scenario and nobody expects 
100% concordance. However, this does not condone the 
poor uptake of advice (see below).
The importance of CPG to clinicians is that health-
care administrators, regulators, and policy-maker payers 
are starting to consider that CPGs represent standards 
of care. It behoves us to understand all the reasons for 
non-compliance.
CPG undergo three separate phases: development, dis-
semination and implementation. This paper discusses the 
implementation and why clinicians are non-compliant.
Effect of guidelines on clinical 
outcomes
A guideline can only describe how the evidence suggests 
that clinical practice should be undertaken. It has to be 
digested and implemented. In 1986, a national CPG on 
caesarean sections was published in Canada. The docu-
ment was circulated for consultation and accepted by 
the national specialty association. However, in the years 
following publication, there was no real change in opera-
tion rate despite individual clinicians and organisations 
declaring that they were compliant with the CPG [2]. This 
highlights that CPG can only be of value if they are intro-
duced, implemented and audited to ensure that old prac-
tices are discontinued.
Do guidelines improve care?
When CPG are adhered to, clinical outcomes improve. 
This is well-illustrated anecdotally by the steady increase 
in longevity in patients with myocardial infarction 
in Sweden. Much of the benefit will have come from 
improved diagnostics and treatments but it is well rec-
ognised that there is a slow translation of research find-
ings into clinical practice. Over the years CPG have been 
written in an attempt to both speed up the introduction of 
good practice and also to reduce variability between units. 
Data from Sweden shows that when CPG are agreed and 
implemented, there is a steady increase in the uptake of 
treatments and a consequent steady fall in mortality [3].
The literature on the beneficial effects of CPG is not 
entirely convincing. Two systematic reviews of the effect 
on outcomes have been performed. The first showed that 
55/59 studies showed improvement but since the review 
only assessed randomised controlled trials (RCT), it is 
hardly surprising that there was such a high rate of com-
pliance since they would have been performed under 
supervision by trial managers [4]. A second studied the 
outcome of CPG in Holland. This country was chosen as it 
has a long history of CPG production and it was assumed 
that CPG were embedded into the consciousness of prac-
titioners. Studies were selected if they measured adher-
ence or outcome and were evidence-based or RCT. A total 
of 30 studies (some with multiple outcomes) were found 
but only nine studies assessed patient outcomes; six 
showed significant improvement in some outcomes; four 
showed modest improvements in some outcomes; and 
three showed no effect on patient outcomes. A greater 
benefit was found on the process of care [5]. From these 
two reviews it is clear that high quality research on CPG 
is still necessary.
Not all physicians follow guidelines
Numerous studies have highlighted the failure of cli-
nicians to follow CPG. These have shown that non-
compliance is as high as 70% and occurs across most 
disciplines and countries [2, 6–9]. One important aspect 
that has not been well studied is that of the age of prac-
titioners. There has been a change in practice over the 
generations with those clinicians in the second half of 
their careers practising as individuals according to their 
experience and knowledge whereas the younger genera-
tions are practising in a more collaborative team-based 
medicine which is more strongly influenced by protocols 
and guidelines [10].
Consequence of guideline failure
As there have been few good studies of CPG, the evi-
dence for the effects of non-compliance will by necessity 
be anecdotal. Gupta and Cook explain a situation where 
an unnoticed glucose infusion influenced finger-prick 
point-of-care glucose test and resulted in hypoglycaemic 
brain damage [1]. They noted that there were numerous 
confounding errors in addition to the primary error. These 
errors occurred despite guidelines designed to prevent 
this scenario having been published several years previ-
ously. The critical learning point may be that the error 
was based around a routine procedure with which all staff 
were comfortable – in this case arterial cannulation on an 
intensive care unit.
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What are the barriers to guideline 
compliance?
Most of the primary barriers to uptake of guidelines are 
fairly easy to identify [11]. They include awareness, famili-
arity and agreement with the contents. Secondly, respon-
sible clinicians must feel that they have the skills and are 
therefore able to deliver on the CPG. The clinician also 
needs to be able to overcome the inertia of “normal prac-
tice” and understand the need for change. Thirdly, the 
goals of the clinician and the patient are not always the 
same as each other (or the guideline). Finally, there are 
a multitude of external barriers, e.g. equipment, space, 
educational materials, time, staff, and financial resource. 
In view of the considerable energy that has been placed 
on guidelines, there has been extensive research into their 
uptake.
Barriers identified by clinicians
The Dutch have had the longest history of introducing the 
culture of CPG into clinical practice and as such they have 
been the single group who have been most extensively 
studied. Indeed, a recent survey of Dutch primary care 
physicians showed that in excess of 94% of respondents 
believed that CPG are useful sources of advice and based 
on sound evidence. Ninety percent present believe that 
the use of CPG would lead to better outcomes. However, 
35% reported having difficulty in changing personal rou-
tines to adopt CPG and 6% admitted to being resistant to 
adhering with CPG [12]. A further study of primary care 
physicians across Europe gave similar results with 90% 
agreeing with the content of CPG and 80% reporting use 
of them (see Table 1) [13]. This latter group highlighted 
barriers of lack of time (38%) and patient compliance 
(17%). They also reported that improved implementation 
would require more education for physicians (29%) and 
patients (25%); publishing and promoting CPG (23%); and 
simplifying the guidelines. Unfortunately, these clinicians 
seemed to focus only on barriers that were firmly in other 
people’s domain.
Other barriers (Table 2)
CPG vary in their detail. Some are brief and give clear 
instructions. Others are complex with multiple rules some 
of which may conflict with other CPGs. They may give 
options which are appropriate for the experienced clini-
cian but which can become bewildering for the less skilled 
or non specialist clinician. This causes confusion and is 
likely to lead to the CPG not being followed [11, 14]. The 
need for easily accessible CPG written with short concise 
summaries has been specifically identified as a require-
ment by surveys from both primary and secondary care 
in Spain [15]. An observational study in the UK showed 
that CPG were less likely to be followed if they contained 
controversial recommendations or statements that were 
vague [16]. The latter may be a result of either writing 
guidance for, or interpreting guidance in, clinical situa-
tions that do not clearly match the scenario for which the 
CPG was written.
Clinicians cannot always agree with guidelines. A 
good example is the definition of hypothyroidism. This 
was addressed by the commissioning of a systematic 
review by all the major endocrine societies in the US – the 
Endocrine Society, the American Thyroid Association and 
the American Association of Clinical Endocrinologists and 
published in 2004 [17]. Unfortunately the officers of the 
Table 1: Surveys of primary care physicians on CPG.
  Dutch clinicians (A)   Clinicians from France, Germany, 
Italy, Sweden and UK (B)
CPG are useful source of advice   97%   89%
CPG based on sound evidence   94%  
Use of CPG would lead to better outcomes   90%  
Difficulty changing personal routines   35%  
Personal skills complicate compliance   14%  
Clinician resistant to adhering to CPG   6%  
Clinicians report use of CPG     81%
Clinicians report lack of time to be compliant     38%
Clinicians report lack of patient compliance     17%
Surveys of primary care physicians regarding their views on CPG. Column A see ref. # 12. Column B see ref. # 13.
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specialist societies not only disagreed with the definition 
of hypothyroidism resulting from the systematic review 
[18] but subsequently broke into two opposing camps 
each of which wrote contrasting critiques despite using 
the same data sources [19, 20]. A further example of dif-
ferent data interpretation is in the field of heart failure 
where the guideline from the National Institute for Health 
and Care Excellence (NICE) in England, disagrees with the 
guidelines of the combined cardiac specialist societies in 
the US over the diagnostic utilities of BNP and echocar-
diography in the diagnosis/exclusion of heart failure [21]. 
Furthermore, a recent editorial in JAMA highlighted the 
problems of governance in the process of writing CPG by 
specialist societies particularly in the opacity of declaring 
conflicts of interest [22].
Compliance with guidelines on the use of laboratory 
blood testing was studied in Holland. This found that 
in general practice, non-compliance is predominantly 
caused by adding on extra tests. Van Wijk et al. concluded 
that the non-compliance might be due to practitioners 
applying new medical insight before it is incorporated in a 
revision of that guideline and in fact clinicians were trying 
to improve a guideline that they perceived as being out of 
date [23].
The actual reasons for non-compliance with CPG 
are difficult to generalise as there may be more than one 
recommendation within a guideline; and the reasons for 
non-compliance may be different between guidelines. 
Lugtenberg et al. studied the causes in three guidelines – 
on red eyes, stroke and thyroid disease. They found that 
there were different reasons for non-compliance associ-
ated with each CPG and, moreover, that clinicians and 
patients have different views of their non-applicability 
[14, 24].
Table 2: Reasons for non-compliance.
CPG   CPG are too complex
  Multiple rules in a single CPG
  Disagreement with the CPG
  Multiple (and conflicting) rules between CPG
  Perception that a guideline that is out of date
  Different aspects of a guideline have different 
reasons for non compliance
Clinicians   Physicians not good at assessing risk [38, 39]
  Overconfidence
  Time pressures [26]
  Information overload
  Difficulty in changing usual practice
  Fragmentation of care
  Case complexity
  Different clinicians have different reasons
Berner and Graber comprehensively reviewed the 
effect of physician over confidence in their own ability 
as a cause of diagnostic errors. They state that physicians 
believe that their practice does conform to consensus rec-
ommendations even though it does not. They also show 
that physicians tend to underestimate clinical risk. They 
also raise the issue that it is necessary to make the correct 
diagnosis in order to follow the appropriate CPG. However, 
they further note that failure to follow a CPG does not nec-
essarily lead to poor patient outcomes [25].
Other reasons for non-compliance include time pres-
sures [26], information overload [27] and difficulty in 
changing from previous practice to the CPG protocols 
[16]. Furthermore, in our current pressurised health care 
systems with multi-disciplinary teams, there is the issue of 
fragmented care. This occurs when a large team of people 
are involved in the care of a patient which may result in 
uncertainty between different professional groups over 
their responsibility for various actions. This confusion 
may lead to resentment and subsequently disregard for 
policies and guidelines [28].
CPG are written for specific symptoms or diseases 
but as medicine advances, patients no longer fit into the 
clean categories of the evidence-based trials that the CPG 
are based upon. Patients age. They develop multiple co-
existent diseases and may already have had the first line 
treatment covered by the CPG. A systematic review of 
guidelines looking at the effect of case complexity and 
comorbidities found that few CPG addressed co-morbid-
ities and unconnected combinations of diseases. They 
concluded that CPG should state their applicability in 
complex situations [29]. 
CPG and laboratory medicine
There are relatively few CPG written purely for laboratory 
medicine but there are many that are written with labora-
tory tests included. The publication of these CPG should 
not come as a surprise for laboratories that have good 
liaison with their clinicians. These guidelines may involve 
the introduction of new tests and it may take time to make 
the changes within the laboratory to evaluate new tests 
and bring them into the routine repertoire. However, it is 
not always possible to predict how quickly guidelines will 
be implemented. The implementation of troponin testing 
in the UK was very slow whilst clinicians learnt how to 
interpret the new test [30]. In contrast, the NHS in England 
issued a guideline for the enhanced investigation of car-
diovascular disease and diabetes and this had an imme-
diate effect with major increases in laboratory workload 
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for the prescribed tests (plasma glucose, cholesterol, TFT, 
HbA1c and urine microalbumin) in primary care – possibly 
because it included a contract for payment [31].
How well do laboratories follow CPG?
In the absence of many guidelines, there have been many 
surveys of laboratory practice to determine peer practice. 
These are mostly descriptive and do not, in themselves, 
have any impact on laboratory practice. However, a 
recent report of practice of cardiac testing is valuable as 
a marker for laboratory compliance with CPG. Guidelines 
for the investigation of chest pain have been available for 
many years. Collinson et  al. studied laboratories across 
Europe on two occasions [32]. They reported that whilst 
laboratories are variably compliant, there has been little 
change over the 4  years of their study despite the well-
publicised CPG and much of the evidence having been 
published in laboratory medicine journals. This finding 
mirrors the unexplained huge variability in reference 
intervals reported by laboratories and suggests that more 
attention to the clinical interface of the laboratory service 
is needed.
Are laboratory specialists likely to follow 
guidelines?
There has been little research on the behaviour of labo-
ratory medicine in regard to CPG. A single study from 
Norway suggests that laboratory medicine departments 
are as a poor as clinicians in other disciplines [33]. 
Therefore, we surveyed senior members of the Associa-
tion for Clinical Biochemistry and Laboratory Medicine 
in January 2015 [Barth JH unpublished data 2015]. The 
survey asked questions regarding the NACB Diabetes 
Mellitus guideline [34] and NICE Chronic Kidney Disease 
[35] and also asked about the responsibility for ensuring 
uptake of guidelines.
The compliance rates and reasons for non-compliance 
are illustrated in Table 3. The low compliance for the CKD 
guideline is due to the cost of introducing cystatin C. It is 
important to note the significant number of individuals 
who disagree with the (or parts of the) guideline recom-
mendations. The questionnaire did not explore reasons 
underlying that opinion. Overall the pattern of reasons 
for non-compliance is similar to the previous reported 
surveys of clinicians.
The questionnaire asked who was responsible for 
implementing CPG. There was no clear answer as to 
whether this should be the laboratory medicine specialist, 
the senior managing pathologist or the medical director 
of the hospital. Respondents were clear that national and 
international guidelines were more important than local 
CPG.
Laboratory tests in clinical guidelines
It has already been mentioned that CPG are often written 
without help from laboratory medicine specialists with 
the result that the laboratory aspects of CPG are diffi-
cult to implement in a way that ensures optimal use of 
laboratory tests. This has been addressed by the Working 
Group on Guidelines of the European Federation Clini-
cal Chemistry and Laboratory Medicine and the Euro-
pean Union of Medical Specialists. We studied a number 
of (inter)national guidelines and developed a checklist 
to help guideline authors. We also determined which 
aspects of the total testing process were the areas which 
needed most encouragement [36]. The checklist contains 
Table 3: Survey of laboratory medicine specialists.
  Guideline 1 – diabetes  Guideline 2 – CKD
I am complaint with this guideline   40%   12%
Reason for non-compliance   yes (%)   yes (%)
 I do not have the time   13   13
 Disagree with guidance   32   46
 The guidance is irrelevant to my practice   3   2
 Not supported by my local management and/or colleagues   24   51
 This guidance is too complex to implement   10   18
 Guideline is too rigid   33   23
  Implementing this guidance would mean wasting resources that 
could be really useful elsewhere
  17   22
Survey of ACB (UK) members in January 2015 regarding CPG. This Table explains the reasons for non compliance.
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80 points: 33 pre-analytical, 37 analytical and 10 post- 
analytical. Only 30% of the items were covered by the 
guidelines but, encouragingly, those guideline groups with 
laboratory medicine specialist covered more. It is of note 
that the important features of patient preparation; bio-
logical and analytical variations and sample handling were 
rarely included. A second study of CPG related to chest pain 
showed that CPG were similarly poor in these areas [37].
How well do national guidelines provide 
 recommendations for laboratory medicine?
A review of the CPG published by the UK National Institute 
for Clinical Excellence (NICE) was undertaken as a model 
for other (inter)national bodies. A total of 39 CPG from 
NICE were relevant to laboratory medicine. There were 
relatively few recommendations about laboratory tests; 
there were five recommendations about tests that should 
be done and 10 recommendations for tests that might be 
done; and nine recommendations for tests that should not 
be done. In fact the only specific recommendations were 
that decision making values for BNP/NT pro-BNP and 
CA125 were defined [Barth JH unpublished data 2015].
What do we do now?
CPG do improve patient care and outcomes so laboratory 
medicine does need to address them. We need to under-
take further research into the diagnostic utility of our tests 
so that these aspects of the testing process are found in 
literature searches. Secondly, we need to make sure that 
all guideline committees have a specialist in laboratory 
testing on the writing committees. This is necessary to 
ensure that our analytical efforts are rewarded with appro-
priate samples taken for optimal diagnostic use.
Summary
There is good evidence to suggest that CPG improve patient 
outcomes and over the past three decades, CPG have been 
written in many areas of clinical medicine. Few have been 
written for laboratories and the ones that affect labora-
tories are inadequate in that respect. We need to change 
this culture and ensure that we are involved in both the 
arenas of diagnostic research and guideline writing. 
Indeed, one of the drivers for CPG in laboratory medicine 
is to ensure that diseases are not under- or over-diagnosed 
and therefore patients are not under- or over-treated due 
to incorrect interpretation of investigations.
Much of the evidence reviewed in this article is based 
on studies of clinicians but it is pertinent to consider the 
conclusion that Collinson made regarding current labo-
ratory practice in regard to cardiac markers. “There is 
no longer a debate about which test should be used for 
the diagnosis of MI. The question is why do laboratories 
persist in non-evidence-based behaviour? And why are 
they not talking with their clinicians?” [32].
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